Literature DB >> 26084608

HMGB1 overexpression correlates with poor prognosis in early-stage squamous cervical cancer.

Yirong Xu1, Zhenwen Chen2, Guangheng Zhang2, Yanfeng Xi3, Ruifang Sun3, Fei Chai2, Xiaogang Wang2, Jianhong Guo3, Lin Tian4.   

Abstract

High mobility group box 1 (HMGB1) is associated with tumor progression and a poor prognosis; microtubule-associated protein 1 light chain 3 (LC3) plays a critical role in autophagy. However, the roles of HMGB1 and LC3 in squamous cervical cancer (SCC) remain unclear. An array of 166 early-stage SCC, 62 cervical intraepithelial neoplasia (CIN), and 50 normal cervical tissue samples was assessed. HMGB1 and LC3 protein levels were examined by immunohistochemistry, and the associations of HMGB1 and LC3 levels with clinicopathological characteristics evaluated, to assess their prognosis significance. High nuclear HMGB1 levels were detected in 72.9% SCC cases; 16% cases showed cytoplasmic expression of HMGB1 in cancer cells with low nuclear expression. Interestingly, HMGB1 levels in SCC samples were significantly higher than CIN and control specimens, while lower LC3 expression was found in SCC samples (P < 0.001). Nuclear HMGB1 expression was weakly negatively correlated to LC3 amounts (r = -0.254, P = 0.001). High nuclear HMGB1 levels were associated with vascular metastasis (P < 0.05). In addition, cytoplasmic HMGB1 expression was associated with lymph node metastasis (P < 0.05). Furthermore, high nuclear HMGB1 levels and cytoplasmic HMGB1 expression predicted poor overall survival (OS) and disease-free survival (DFS). Meanwhile, high LC3 expression was associated with favorable prognosis. Multivariate analysis showed that both nuclear and cytoplasmic HMGB1 expressions were independent prognostic factors for overall- and disease-free survival, along with nodule metastasis. HMGB1 overexpression plays a significant role in SCC progression. Both nuclear and cytoplasmic HMGB1 are independent factors for poor prognosis in early-stage SCC.

Entities:  

Keywords:  Cervical cancer; High mobility group box 1 (HMGB1); Microtubule-associated protein 1 light chain 3 (LC3); Prognosis

Mesh:

Substances:

Year:  2015        PMID: 26084608     DOI: 10.1007/s13277-015-3624-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  49 in total

1.  Expression of Beclin 1 and LC3 in FIGO stage I-II cervical squamous cell carcinoma and relationship to survival.

Authors:  Weipei Zhu; Xiaohong Pan; Feng Li; Yongshen Zhang; Xueguan Lu
Journal:  Tumour Biol       Date:  2012-05-25

2.  Growth factor regulation of autophagy and cell survival in the absence of apoptosis.

Authors:  Julian J Lum; Daniel E Bauer; Mei Kong; Marian H Harris; Chi Li; Tullia Lindsten; Craig B Thompson
Journal:  Cell       Date:  2005-01-28       Impact factor: 41.582

3.  Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature.

Authors:  Judy R van Beijnum; Ruud P Dings; Edith van der Linden; Bernadette M M Zwaans; Frans C S Ramaekers; Kevin H Mayo; Arjan W Griffioen
Journal:  Blood       Date:  2006-06-22       Impact factor: 22.113

4.  The isolation and purification of the high mobility group (HMG) nonhistone chromosomal proteins.

Authors:  G H Goodwin; E W Johns
Journal:  Methods Cell Biol       Date:  1977       Impact factor: 1.441

Review 5.  Papillomavirus infections--a major cause of human cancers.

Authors:  H zur Hausen
Journal:  Biochim Biophys Acta       Date:  1996-10-09

6.  High-mobility group box 1 is dispensable for autophagy, mitochondrial quality control, and organ function in vivo.

Authors:  Peter Huebener; Geum-Youn Gwak; Jean-Philippe Pradere; Catarina M Quinzii; Richard Friedman; Chyuan-Sheng Lin; Chad M Trent; Ingmar Mederacke; Enpeng Zhao; Dianne H Dapito; Yuxi Lin; Ira J Goldberg; Mark J Czaja; Robert F Schwabe
Journal:  Cell Metab       Date:  2014-03-04       Impact factor: 27.287

7.  The expression of high mobility group box 1 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma.

Authors:  Chen Chuangui; Tang Peng; Yu Zhentao
Journal:  Pathol Oncol Res       Date:  2012-04-29       Impact factor: 3.201

8.  HMGB1 release and redox regulates autophagy and apoptosis in cancer cells.

Authors:  D Tang; R Kang; C-W Cheh; K M Livesey; X Liang; N E Schapiro; R Benschop; L J Sparvero; A A Amoscato; K J Tracey; H J Zeh; M T Lotze
Journal:  Oncogene       Date:  2010-07-12       Impact factor: 9.867

9.  Resveratrol induces cell death in cervical cancer cells through apoptosis and autophagy.

Authors:  Sihomara P García-Zepeda; Enrique García-Villa; José Díaz-Chávez; Rogelio Hernández-Pando; Patricio Gariglio
Journal:  Eur J Cancer Prev       Date:  2013-11       Impact factor: 2.497

10.  The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer.

Authors:  Xiaokun Shen; Lingzhi Hong; Huiming Sun; Minke Shi; Yong Song
Journal:  Oncol Rep       Date:  2009-09       Impact factor: 3.906

View more
  10 in total

1.  Association of single-nucleotide polymorphisms of high-mobility group box 1 with susceptibility and clinicopathological characteristics of uterine cervical neoplasia in Taiwanese women.

Authors:  Hsin-Hung Wu; Yu-Fan Liu; Shun-Fa Yang; Wea-Lung Lin; Shiuan-Chih Chen; Chih-Ping Han; Hsiang-Ling Wang; Long-Yau Lin; Po-Hui Wang
Journal:  Tumour Biol       Date:  2016-10-04

2.  HSP90B1 overexpression predicts poor prognosis in NSCLC patients.

Authors:  YiRong Xu; ZhenWen Chen; GuangHeng Zhang; YanFeng Xi; RuiFang Sun; XiaoGang Wang; WenYan Wang; Fei Chai; XiongFeng Li
Journal:  Tumour Biol       Date:  2016-09-06

3.  Downregulation of HMGB1 by miR-34a is sufficient to suppress proliferation, migration and invasion of human cervical and colorectal cancer cells.

Authors:  Karthik Subramanian Chandrasekaran; Anusha Sathyanarayanan; Devarajan Karunagaran
Journal:  Tumour Biol       Date:  2016-07-25

4.  MiR-1179 inhibits the proliferation of gastric cancer cells by targeting HMGB1.

Authors:  Yongsheng Li; Ce Qin
Journal:  Hum Cell       Date:  2019-03-22       Impact factor: 4.174

Review 5.  High Mobility Group Box 1 in Human Cancer.

Authors:  Bernardo L Rapoport; Helen C Steel; Annette J Theron; Liezl Heyman; Teresa Smit; Yastira Ramdas; Ronald Anderson
Journal:  Cells       Date:  2020-07-10       Impact factor: 6.600

6.  The effect of HMGB1 on the clinicopathological and prognostic features of cervical cancer.

Authors:  Pan Li; Mengfei Xu; Hongbing Cai; Niresh Thapa; Can He; Ziye Song
Journal:  Biosci Rep       Date:  2019-05-02       Impact factor: 3.840

7.  Association of Cell Death Markers With Tumor Immune Cell Infiltrates After Chemo-Radiation in Cervical Cancer.

Authors:  Teodora Oltean; Lien Lippens; Kelly Lemeire; Caroline De Tender; Marnik Vuylsteke; Hannelore Denys; Katrien Vandecasteele; Peter Vandenabeele; Sandy Adjemian
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738

8.  No association between HMGB1 polymorphisms and cancer risk: evidence from a meta-analysis.

Authors:  Xing-Yan Li; Chun-Hua Liang; Ye-Jing Yang; Lei Liu; Yong-Jun Du; Hong-Suo Liang; Lin Li; Bo Zhang; Jian-Min Li; Jin-Min Zhao
Journal:  Biosci Rep       Date:  2018-09-05       Impact factor: 3.840

9.  MicroRNA-935 Inhibits Proliferation and Invasion of Osteosarcoma Cells by Directly Targeting High Mobility Group Box 1.

Authors:  Zhiqiang Liu; Qiang Li; Xin Zhao; Bin Cui; Libo Zhang; Qiang Wang
Journal:  Oncol Res       Date:  2018-02-22       Impact factor: 5.574

10.  Role of Extracellular High-Mobility Group Box-1 as a Therapeutic Target of Gastric Cancer.

Authors:  Wataru Takaki; Hirotaka Konishi; Daiki Matsubara; Katsutoshi Shoda; Tomohiro Arita; Satoshi Kataoka; Jun Shibamoto; Hirotaka Furuke; Kazuya Takabatake; Hiroki Shimizu; Shuhei Komatsu; Atsushi Shiozaki; Takeshi Kubota; Kazuma Okamoto; Eigo Otsuji
Journal:  Int J Mol Sci       Date:  2022-03-17       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.